RCS - Envision Pharma Grp - Envision Pharma Group Appoints Mike Glover to SVP

Sanofi SAAnnouncement

02/05/2023 13:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230502:nRSB0313Ya&default-theme=true

RNS Number : 0313Y  Envision Pharma Group  02 May 2023

Envision Pharma Group Appoints Mike Glover to Senior Vice President, Payer and
HTA Solutions to Drive Acceleration and Expansion in Value & Access and
Data Analytics

PHILADELPHIA, PA / ACCESSWIRE / May 2, 2023 / Envision Pharma Group (Envision)
has appointed Mike Glover to Senior Vice President, Payer and HTA Solutions.
Mike will be responsible for leading and developing Envision's distinctive
market access and HTA strategies for early-stage and late-stage businesses,
combining customer insights, vision, and creativity. Mike's key focus areas
will be transformations in patient access, global pricing strategies,
real-world evidence, and improving patient outcomes.

Meg Heim, CEO of Envision Pharma Group, shares, "I am excited to welcome Mike
to the team at Envision as Senior Vice President, Payer and HTA solutions. As
we continue to accelerate Envision's business expansion, mission, and
commitment to our clients' needs. Mike's extensive experience in developing
and executing cutting-edge access, policy, and pricing strategies while
executing fully integrated market access programs will be critical in
partnering with our clients to execute upon their goals, improve performance,
and meet their unique business needs with the support of our technology
platforms."

Prior to joining Envision, Mike served as Vice President, Head of Global
Access and Pricing Strategy for GlaxoSmithKline. Before that, he held various
leadership positions of increasing responsibilities at GSK, Sanofi, and
Bristol Myers Squibb. He brings with him a diverse background across multiple
geographies, functions, and therapeutic areas. His global commercial
leadership experiences spanning oncology, cardiovascular, diabetes, and
virology from asset development to in-market delivery will be a valuable asset
to Envision.

Mike adds, "The energy and passion of the Envision team shines through in
every interaction I've had. It was this passion and desire to be the very best
at what they do that made this an easy decision for me to join Envision. Our
industry is facing a changing and challenging environment and Envision is
building an organization that will not just deliver, but will become a true
partner for our customers adding real value across the life cycle of a brand.
I am delighted to be joining them at this important time in our industry's
future."

About Envision Pharma Group

Founded in 2001, Envision Pharma Group is a leading global technology-enabled
strategic solutions partner for the life sciences industry, working with over
200 pharma and biotech companies, including 18 of the top 20 pharmaceutical
companies. Envision supports clients across the product life cycle through a
comprehensive suite of services and industry-leading technology solutions that
include artificial intelligence and natural language processing,
commercialization and integrated strategic consulting, evidence-based
scientific communications and engagement, HEOR/market access and data
analytics, medical capabilities, and omnichannel solutions. Learn more at
www.envisionpharmagroup.com (https://pr.report/-puzX18O) .

Contact Information:

Colleen Carter

Associate Director, Communications, Office of the CEO
colleen.carter@envisionpharma.com (mailto:colleen.carter@envisionpharma.com)

1 (508) 505 8856

SOURCE: Envision Pharma Group

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUPUCUAUPWUCP